BioSpace News Archive

Ikena Announces Advancement of TEAD Inhibitor IK-930 into IND-Enabling Studies and Unveils a First-in-Class Preclinical Program Targeting KRAS Signaling BOSTON--( BUSINESS WIRE )-- Ikena Oncology, Inc. (“Ikena”), a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven cancer therapies, today announces the closing of $120 million in an oversubscribed Series B financing. The round was led and syndicated b

Investment led by Deerfield Management Company alongside a strategic equity investment from Eli Lilly and Company

Labcorp, a leading global life sciences company, announced that members of the executive management team will participate in a virtual fireside chat at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12 at 8:20 a.m..

Sebela Pharmaceuticals® today announced that SUTAB® (sodium sulfate, magnesium sulfate, and potassium chloride) tablets, the first tablet colonoscopy preparation to receive approval from the U.S. Food and Drug Administration (FDA) in over 10 years, is now available in the United States.

OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced that its subsidiary Curetis GmbH has entered into a distribution agreement with Annar Health Technologies for Colombia.

Revolution Medicines, Inc., a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, announced that Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman, will deliver a corporate presentation as part of the 39th Annual J.P. Morgan Healthcare Conference.

Dyne Therapeutics, Inc. announced that Joshua Brumm, president and chief executive officer, and Romesh Subramanian, Ph.D., chief scientific officer, are scheduled to present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 10:00 a.m. ET.

Black Diamond Therapeutics, Inc. announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the J.P. Morgan 39th Annual Virtual Healthcare Conference on Tuesday, January 12, 2021 at 7:30 AM ET.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced Novo Nordisk A/S (“Novo”) has nominated its first candidate under the existing agreement between the two companies for the discovery and development of novel therapies for the treatment of liver-related cardiometabolic diseases using Dicerna’s proprietary GalXC™ RNAi platform technology.

Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced that Keith Dunleavy, M.D., chief executive officer and chairman of the board of Inovalon, and Jonathan R. Boldt, chief financial officer of Inovalon, will present at the 39 th Annual J.P. Morgan Healthcare Conference, which will be held virtually. The virtual presentation will take place at 10:00 a.m. (EST) on Tuesday, Januar